Literature DB >> 29276296

Formulary Drug Review: Ocrelizumab.

Zaynah K Ali1, Danial E Baker1.   

Abstract

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Entities:  

Year:  2017        PMID： 29276296      PMCID： PMC5735732          DOI： 10.1177/0018578717731733

Source DB:  PubMed          Journal:  Hosp Pharm        ISSN： 0018-5787


  7 in total

1.  Disease modifying therapies in multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology and the MS Council for Clinical Practice Guidelines.

Authors:  D S Goodin; E M Frohman; G P Garmany; J Halper; W H Likosky; F D Lublin; D H Silberberg; W H Stuart; S van den Noort
Journal:  Neurology       Date:  2002-01-22       Impact factor: 9.910

Review 2.  Therapeutic strategies targeting B-cells in multiple sclerosis.

Authors:  Ron Milo
Journal:  Autoimmun Rev       Date:  2016-03-09       Impact factor: 9.754

Review 3.  Novel Agents for Relapsing Forms of Multiple Sclerosis.

Authors:  Rebecca Straus Farber; Asaff Harel; Fred Lublin
Journal:  Annu Rev Med       Date:  2015-09-17       Impact factor: 13.739

4.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.

Authors:  Stephen L Hauser; Amit Bar-Or; Giancarlo Comi; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Xavier Montalban; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Jerry S Wolinsky; Douglas L Arnold; Gaelle Klingelschmitt; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Peter Chin; Nicole Mairon; Hideki Garren; Ludwig Kappos
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

5.  Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.

Authors:  Xavier Montalban; Stephen L Hauser; Ludwig Kappos; Douglas L Arnold; Amit Bar-Or; Giancarlo Comi; Jérôme de Seze; Gavin Giovannoni; Hans-Peter Hartung; Bernhard Hemmer; Fred Lublin; Kottil W Rammohan; Krzysztof Selmaj; Anthony Traboulsee; Annette Sauter; Donna Masterman; Paulo Fontoura; Shibeshih Belachew; Hideki Garren; Nicole Mairon; Peter Chin; Jerry S Wolinsky
Journal:  N Engl J Med       Date:  2016-12-21       Impact factor: 91.245

6.  Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial.

Authors:  Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik Barkhof; Ming Yin; David Leppert; Robert Glanzman; Jeroen Tinbergen; Stephen L Hauser
Journal:  Lancet       Date:  2011-10-31       Impact factor: 79.321

Review 7.  Multiple sclerosis: a review of the disease and treatment options.

Authors:  Daniel Sturm; Samuel L Gurevitz; Amelia Turner
Journal:  Consult Pharm       Date:  2014-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.